Rhumbline Advisers C4 Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $113 Billion
  • Q2 2025

A detailed history of Rhumbline Advisers transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 2,716 shares of CCCC stock, worth $6,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,716
Previous 89,633 96.97%
Holding current value
$6,138
Previous $143,000 97.9%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
SELL
$1.1 - $1.74 $95,608 - $151,235
-86,917 Reduced 96.97%
2,716 $3,000
Q1 2025

Apr 08, 2025
SELL
$1.6 - $4.09 $16,611 - $42,462
-10,382 Reduced 10.38%
89,633 $156,000
Q4 2024

May 29, 2025
BUY
$3.6 - $7.0 $37,375 - $72,674
10,382 Added 11.58%
100,015 $360,000
Q4 2024

Jan 30, 2025
BUY
$3.6 - $7.0 $15,717 - $30,562
4,366 Added 4.56%
100,015 $360,000
Q3 2024

Nov 12, 2024
BUY
$4.43 - $7.38 $22,274 - $37,106
5,028 Added 5.55%
95,649 $545,000
Q2 2024

Aug 01, 2024
BUY
$4.05 - $8.1 $359,761 - $719,523
88,830 Added 4959.8%
90,621 $418,000
Q3 2023

Nov 09, 2023
SELL
$1.81 - $3.89 $4,083 - $8,775
-2,256 Reduced 55.74%
1,791 $3,000
Q2 2023

Aug 08, 2023
SELL
$2.75 - $3.77 $173,362 - $237,664
-63,041 Reduced 93.97%
4,047 $11,000
Q1 2023

May 11, 2023
BUY
$3.1 - $9.02 $8,636 - $25,129
2,786 Added 4.33%
67,088 $211,000
Q4 2022

Feb 14, 2023
BUY
$5.42 - $10.24 $1,457 - $2,754
269 Added 0.42%
64,302 $379,000
Q3 2022

Nov 10, 2022
BUY
$8.03 - $12.77 $31,967 - $50,837
3,981 Added 6.63%
64,033 $562,000
Q2 2022

Aug 11, 2022
BUY
$5.06 - $26.46 $97,926 - $512,080
19,353 Added 47.55%
60,052 $453,000
Q1 2022

May 12, 2022
BUY
$19.99 - $33.23 $48,435 - $80,516
2,423 Added 6.33%
40,699 $987,000
Q4 2021

Feb 10, 2022
BUY
$29.39 - $46.86 $2,380 - $3,795
81 Added 0.21%
38,276 $1.23 Million
Q3 2021

Nov 12, 2021
BUY
$35.91 - $50.5 $130,353 - $183,315
3,630 Added 10.5%
38,195 $1.71 Million
Q2 2021

Aug 05, 2021
BUY
$30.39 - $42.18 $737,990 - $1.02 Million
24,284 Added 236.2%
34,565 $1.31 Million
Q1 2021

May 06, 2021
BUY
$31.96 - $46.5 $53,980 - $78,538
1,689 Added 19.66%
10,281 $380,000
Q4 2020

Feb 10, 2021
BUY
$22.8 - $37.05 $195,897 - $318,333
8,592 New
8,592 $285,000

Others Institutions Holding CCCC

# of Institutions
105
Shares Held
57.2M
Call Options Held
15.2K
Put Options Held
0
View Full List

About C4 Therapeutics, Inc.

CCCC Quotes by TradingView
  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $111M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email